, according to a new report in the journal
. The child had a rare, deadly brain disease called ataxia telangiectasia, or A-T. The disease can lead to degeneration of a region of the brain; most people with A-T die by their teens or early 20s. The boy had traveled to Russia at age 9, when he was injected with fetal neural stem cells in his brain and spinal cord, the Associated Press reports. He received two additional sets of injections at ages 10 Read the rest of this entry »

.
Dr. Steven Teitelbaum, a pathology and immunology professor at
, said scientists there were enthused about the prospect of advancing research with embryonic stem cells but also shared a word of caution about expectations.
“We want to see the promise of this therapy move forward,” he said Friday. “But we have to be careful about expectations. This is not a clinical trial to test whether embryonic stem cells will work therapeutically. Read the rest of this entry »

This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, the risks and
uncertainties that could affect the development of Zevalin include risks
associated with preclinical and clinical developments in the biopharmaceutical
industry in general and with Zevalin in particular including, without
limitation, Read the rest of this entry »

Induced pluripotent stem cells are derived from an adult stem cell using genes and viruses. Researchers have tried to improve this method by developing a safer way to obtain stem cells from adult cells without using the viruses that can cause cancer. Last year, researchers at the Massachusetts General Hospital and Harvard Medical School in Boston managed to reprogram adult skin cells into embryonic-like stem cells using adenoviruses which don’t Read the rest of this entry »

JEFFERSON CITY, Mo. (Legal Newsline)-Pointing to his father’s battle with diabetes, Missouri Attorney General Chris Koster praised the Food and Drug Administration’s decision to allow testing using human embryonic stem cells.
“As the son of a man who battled diabetes, I believe stem cell research is an important channel to fight disease,” Koster said in a statement.
Last week, the FDA gave a green light to Menlo Park, Calif.-based biotechnology Read the rest of this entry »

The FDA recently permitted Geron Corp., a biotech company in California, to test embryonic stem cells in human patients for the first time.
Apparently deciding to forego the numerous ethical and safety concerns associated with this practice, the FDA gave Geron the green light the same week President Barack Obama was inaugurated. This is undoubtedly a sample of the “change” we have been promised.
Geron should abandon the limelight in Read the rest of this entry »

Jan 27, 2009 (Datamonitor via COMTEX) –
— Following discussions with the FDA, Cell Therapeutics will attempt to secure approval of pixantrone in relapsed aggressive non-Hodgkin’s lymphoma before the end of 2009. Given the lack of a therapeutic standard within this indication, pixantrone’s chances of approval are high.
Cell Therapeutics expects to begin submission of a rolling new drug application (NDA) for pixantrone in the first quarter of Read the rest of this entry »

AMA asks all state lawmakers pass laws limiting driver cell phone use. National doctors organization urges states to protect consumers from injury and death.
December 23, 2008, West Palm Beach, FL (JusticeNewsFlash.com)–Justice roadway safety advocates and West Palm Beach auto accident lawyers are joining the American Medical Association’s (AMA) http://www.ama-assn.org/ ban against text messaging while driving initiative. In early November Read the rest of this entry »

Using stem cells is controversial because embryonic stem cells are taken from human fetuses. 
Earlier this month, Glasgow researchers were planning a “major trial” to test the
, according to the BBC. The United Kingdom approved the trial after the US Food and Drug Administration rejected the proposal from ReNeuron, the company that developed the therapy, two years ago.
According to Medical News Today, “
. However, the rest Read the rest of this entry »

CELL-DYN Emerald Designed to Deliver Quick, Reliable Results for Small to Mid-Sized Laboratories
Abbott Park, Illinois (
) — Abbott today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new, compact hematology instrument, CELL-DYN Emerald™. Abbott’s CELL-DYN Emerald will expand the company’s hematology platform by offering a high performance, affordable solution for small to mid-sized clinical Read the rest of this entry »